Literature DB >> 19704055

Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates.

William Patrick McGuire.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19704055     DOI： 10.1200/JCO.2009.23.6653

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  12 in total

1.  Rethinking ovarian cancer: recommendations for improving outcomes.

Authors:  Sebastian Vaughan; Jermaine I Coward; Robert C Bast; Andy Berchuck; Jonathan S Berek; James D Brenton; George Coukos; Christopher C Crum; Ronny Drapkin; Dariush Etemadmoghadam; Michael Friedlander; Hani Gabra; Stan B Kaye; Chris J Lord; Ernst Lengyel; Douglas A Levine; Iain A McNeish; Usha Menon; Gordon B Mills; Kenneth P Nephew; Amit M Oza; Anil K Sood; Euan A Stronach; Henning Walczak; David D Bowtell; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

2.  Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis.

Authors:  Lisa M Hess; Nan Rong; Patrick O Monahan; Paridha Gupta; Champ Thomaskutty; Daniela Matei
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

3.  miRNA-574-3p inhibits metastasis and chemoresistance of epithelial ovarian cancer (EOC) by negatively regulating epidermal growth factor receptor (EGFR).

Authors:  Pengnan Zhang; Jie Zhu; Ya Zheng; Haiyan Zhang; Hong Sun; Shujun Gao
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

4.  Protein tyrosine phosphatase receptor type R (PTPRR) antagonizes the Wnt signaling pathway in ovarian cancer by dephosphorylating and inactivating β-catenin.

Authors:  Yuetong Wang; Jian Cao; Weiwei Liu; Jiali Zhang; Zuo Wang; Yiqun Zhang; Linjun Hou; Shengmiao Chen; Piliang Hao; Liye Zhang; Min Zhuang; Yang Yu; Dake Li; Gaofeng Fan
Journal:  J Biol Chem       Date:  2019-10-25       Impact factor: 5.157

5.  Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.

Authors:  Hatice Ozer; Goncaimir Yenicesu; Sema Arici; Meral Cetin; Ersin Tuncer; Ali Cetin
Journal:  Diagn Pathol       Date:  2012-09-20       Impact factor: 2.644

Review 6.  Ovarian cancer treatment: The end of empiricism?

Authors:  Stephanie Lheureux; Katherine Karakasis; Elise C Kohn; Amit M Oza
Journal:  Cancer       Date:  2015-06-10       Impact factor: 6.860

7.  RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancer.

Authors:  Katia Y Cáceres-Gorriti; Euridice Carmona; Véronique Barrès; Kurosh Rahimi; Isabelle J Létourneau; Patricia N Tonin; Diane Provencher; Anne-Marie Mes-Masson
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

8.  The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma.

Authors:  Euan A Stronach; Paula Cunnea; Christina Turner; Tankut Guney; Radhika Aiyappa; Senthuran Jeyapalan; Camila H de Sousa; Alacoque Browne; Nesreen Magdy; James B Studd; Ruethairat Sriraksa; Hani Gabra; Mona El-Bahrawy
Journal:  Oncotarget       Date:  2015-10-13

9.  Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.

Authors:  Hubert Fleury; Euridice Carmona; Vincent G Morin; Liliane Meunier; Jean-Yves Masson; Patricia N Tonin; Diane Provencher; Anne-Marie Mes-Masson
Journal:  Oncotarget       Date:  2017-06-20

10.  Functional Analyses of RUNX3 and CaMKIINα in Ovarian Cancer Cell Lines Reveal Tumor-Suppressive Functions for CaMKIINα and Dichotomous Roles for RUNX3 Transcript Variants.

Authors:  Karolin Heinze; Daniel Kritsch; Alexander S Mosig; Matthias Dürst; Norman Häfner; Ingo B Runnebaum
Journal:  Int J Mol Sci       Date:  2018-01-15       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.